Introduction {#Sec1}
============

Mouse embryos form five pairs of mammary rudiments (MRs). Their formation is preceded by the formation of three *Wnt10b-*expressing mammary streaks in the axilla, inguen, and in between forelimb and hindlimb respectively around embryonic day (E) 10.5. These streaks fuse into one continuous mammary line (ML) on each flank by E11.5, on which MRs develop in asynchronous fashion and not in numerical sequence, with MR1 in the axilla; MR2, MR3 and MR4 on the flank; and MR5 in the inguen \[[@CR1]\].

The Hedgehog (Hh) pathway was among the first signaling cascades tested for a role in murine mammogenesis, but is not required for it \[[@CR2], [@CR3]\]. Nonetheless, *Extratoes* (*Xt*) mice, which harbor a spontaneous, functional null-mutation for the transcription factor *Gli3*, exhibit multiple defects in prenatal mammary development \[[@CR4]--[@CR7]\].

Given the role of Gli3 in Hh signaling, we provide a brief overview of Hh signaling and Gli transcription factors, followed by their functions in mammogenesis in mouse embryos.

Signal Transduction via Hedgehog and Gli Proteins {#Sec2}
=================================================

Mammals possess three orthologues of the *Drosophila* segment polarity gene *Hedgehog*; *Sonic hedgehog* (*Shh*), *Indian hedgehog* (*Ihh*), and *Desert hedgehog* (*Dhh*) \[[@CR8], [@CR9]\]. While embryonic expression and function of Dhh is restricted to spermatogenesis and Schwann cells, *Shh* and *Ihh* are widely expressed and encode secreted morphogens with well-known roles for Shh in neural tube, limb and somite development and for Ihh in chondrogenesis \[[@CR10], [@CR11]\].

In canonical Hh signaling, Hh molecules bind their twelve-transmembrane receptor Patched1 (Ptch1) or Ptch2. Ptch then derepresses the seven-transmembrane protein Smoothened (Smo), which becomes activated. Through intracellular signaling complexes -whose components have not been studied in embryonic mammary development and are thus not described here- Smo activation converges on the Gli family of Krüppel-type zinc-finger transcription factors, comprising Gli1, Gli2 and Gli3. *Gli1* is expressed when Hh signaling is active, and encodes the transcriptional activator Gli1^A^. *Gli2* and *Gli3* can be expressed in the absence of Hh signaling, in which case their protein products are cleaved to render transcriptional repressors (Gli2^R^, Gli3^R^). Gli2 requires less active Hh signaling than Gli3 to remain uncleaved and function as a transcriptional activator (Gli2^A^, Gli3^A^). Among Gli transcriptional targets are *Gli1* and *Ptch1*, which provide regulatory feedback loops for Hh signaling \[[@CR12], [@CR13]\].

Recently, deviations from this canonical paradigm have been discovered \[[@CR14]\]. They need further exploration, but certainly point to three additional, "non-canonical" signaling scenarios: 1) Signaling involving Hh pathway components independently of Gli-mediated transcription, such as Shh-mediated ERK activation in mammary epithelial cells without Smo-activation \[[@CR15]\]; 2) Direct interaction of Hh signalling components with other molecular pathways; potentially relevant for mammogenesis is the role of Wnt signaling in expression and function of Gli proteins \[[@CR16]\], and 3) "Non-contiguous" or "atypical" interaction of core Hh pathway components with each other.

Pleiotropic Functions of Gli3 in Mammary Development {#Sec3}
====================================================

Studies of the role of Hh signaling components in mammogenesis began in the late 1960's, when D.R. Johnson identified and characterized a mouse strain which he named *Extra-toes* (*Xt*), after the prominent polydactyly in all four paws of heterozygotes \[[@CR4]\]. In E13 embryos homozygous for this spontaneous, semi-dominant mutation, he also found a reduced number of MRs between the forelimb and hindlimb. Because his wild type control had a supernumerary MR near MR3, he concluded that "*the number of nipples visible in Xt/Xt mice at this stage is reduced from four to two pairs, the most anterior and posterior ones persisting*" \[[@CR4]\]. Note that Johnson was mistaken in three aspects: 1) what he referred to as nipples were in fact mammary buds, which precede nipple formation \[[@CR17]\]; 2) had he taken a proper control, he would have concluded that only one MR (MR3) was missing on the flank; 3) had he known that wild-types also form MRs behind the forelimb (MR1) and hindlimb (MR5), he would have noticed an absence of MR5 in *Xt/Xt* embryos \[[@CR5]--[@CR7], [@CR18]\]. Additional *Xt/Xt* mammary defects are described below.

At The Jackson Laboratory arose a spontaneous mouse mutant, named *Xt*^*J*^ because it phenocopies Johnson's *Xt* mutant \[[@CR19]\]. *Xt*^*J*^ mice carry a 51.5 kb deletion downstream of nucleotide 1670 of *Gli3*, including the DNA-binding zinc fingers and thus abolishing both Gli3^A^ and Gli3^R^ functions \[[@CR19]--[@CR21]\], without loss of other known functional sequences. These renamed *Gli3*^*Xt-J*^ mice represent a good model for the human Greig cephalopolysyndactyly syndrome (GCPS), which can be a sporadic or inherited trait, caused by heterozygous loss-of-function mutations of the *GLI3* gene. The syndrome is characterized by polysyndactyly of hands and feet, hypertelorism, and skull abnormalities including craniosynostosis at variable penetrance \[[@CR19], [@CR22]\]\[OMIM 165240, 175700\], the latter seen in mice only when homozygous mutant \[[@CR23]\].

While no mammary phenotypes have been reported for GCPS patients and *Gli3*^*Xt-J/+*^ mouse mutants, *Gli3*^*Xt-J/Xt-J*^ embryos fail to induce MR3 and MR5 \[[@CR5]--[@CR7], [@CR18]\]. Moreover, their MR2 and MR4 are hypoplastic; MR2 protrudes in females \[[@CR18]\] (compare Fig. [1t](#Fig1){ref-type="fig"} with [1l](#Fig1){ref-type="fig"}), resembling MRs of wild-type male embryos \[[@CR17]\], and also exhibits impaired branching morphogenesis; while MR1 is hardly affected \[[@CR18]\]. The *Xt*^*J*^ mutation thus exemplifies that all mammary glands are different and can develop inter-independently \[[@CR24]\]. The question then arises via which molecular mechanisms and tissue-interactions Gli3 regulates formation and development of MR2-5.Fig. 1Expression patterns of *Gli1*, *Gli2* and *Gli3*, and models of tissue- and molecular interactions involving Gli3 in mammary development. **a**--**q** Cross-sections of wild-type embryos and (**r**--**w**) *Gli3*^*Xt-J/Xt-J*^ embryos at E11.5-E13.5 hybridized with ^35^S-labeled RNA-probes for *Gli1*, *Gli2* and *Gli3*. Magnification of **r**-**w** is twice that of **a**--**q**. Insets in **t'** and **u'** present wild-type MR2 from **l'** respectively **m'** at the same magnification. MRs are indicated by *number*. *Black arrow* in **a**--**c** indicates emerging MR3 at E11.5. *White arrowheads* in **r'**, **t' s'** and **u'** point to MM expression. **x** Cartoon of a lateral view of a mouse embryo. Between E10.5 and E11.5 *Gli3* is expressed in the limb buds and all somites (*outlined in gray and numbered*). *Gray shades* represent overlapping in expression with *Fgf10*, the intensity positively correlating with level of *Fgf10* expression. Note the proximity of the overlapping somitic expression to MR3 and MR2, and overlapping limb mesenchymal expression to MR1, MR2, MR4 and MR5. MR1 and MR5 are hidden behind the limbs. **y** Model exclusively for formation of MR3: See main text for explanation. **z** Model for Gli3-mediated repression of *Gli1* in the ME (*bud shape*) and contiguous MM (*darker shade of gray* surrounding mammary bud), based on expression data in panels **a**--**w** and in \[[@CR5], [@CR6]\]. In the absence of *Gli3*, *Gli1* is misexpressed in the MM of MR1, MR2 and MR4, indicating Gli3^R^ normally represses *Gli1* expression. Whether this occurs tissue-autonomously (*intact block arrow*) or via tissue interactions (*broken block-arrow*) remains unclear. Abbreviations: li: liver, r: rib primordium, st: stomach, wt: wild-type

Prior to and at the time of ML and MR formation, *Gli3* is not expressed in the surface ectoderm \[[@CR5]\], from which the MRs derive \[[@CR25]\], but is expressed in the limb mesenchyme, and in the somites in the region between fore- and hindlimbs \[[@CR5]\] (Fig. [1c](#Fig1){ref-type="fig"}). Given the earlier implications of somitic involvement in the establishment of the mammary streak along the flank and in MR induction \[[@CR1], [@CR7]\], the somitic *Gli3* expression was of interest. Indeed, the ventral elongation of the somites including expression of *Gli3* in all thoracic and lumbar somites, and *Fibroblast growth factor (Fgf)10* in thoracic somites \#12 to \#18, determines the position of the ML on the dorso-ventral body axis \[[@CR5]\]. The absence of MR3 in *Gli3*^*Xt-J/Xt-J*^ embryos \[[@CR5]\] is due to reduction of somitic *Fgf10* expression, in particular the relatively high *Fgf10* expression in somite \#15 underlying MR3 \[[@CR5]\]. As MR2 is located above somite \#12 \[[@CR5]\], reduced somitic *Fgf10* expression may be involved in impaired development of MR2 as well.

It is most likely that somitic Gli3 indirectly activates somitic *Fgf10* independent of Shh signaling (\[[@CR5]\] and references therein). Somitic FGF10 may reach and activate the ectodermal FGFR2b via diffusion and/or transportation by dermal precursor cells that delaminate from the somites. This cascade leads to ectodermal cell elongation, *Wnt10b* marker expression, and canonical Wnt signaling as required for ML and MR formation, but only at the level of MR3 \[[@CR5]\], and possibly MR2. These insights finally gave some molecular explanation for the capacity of the dermal mesenchyme to induce MR formation as recognized four decades earlier \[[@CR25]--[@CR27]\].

However, at the level of MR4 and MR5, *Fgf10* is not expressed in the somites. Given that null mutants for either *Gli3* or *Fgf10* fail to induce MR5 and both genes are expressed in the adjacent limb mesenchyme \[[@CR5]\] (Fig. [1x](#Fig1){ref-type="fig"}), it is tempting to speculate that an epistatic interaction between these molecules may also exist in the limb mesenchyme and be required for induction of MR5. The compromised induction of MR2 and MR4 in the absence of *Gli3* can perhaps be attributed to Gli3-independent residual expression of *Fgf10* and other genes in the thoracic somites and limb mesenchyme.

The cellular functions of Gli3 during early mammary growth and morphogenesis are fourfold, and the same in all MRs \[[@CR18]\]: downregulation of 1) cell proliferation and 2) cell apoptosis in epithelial cells of the ML and MRs; 3) mediation of ectodermal cell recruitment into MRs, which contributes to MR growth until at least E14.5; 4) hypertrophy of the basal/peripheral cells of the ME, which provides a large proportion of the growth between E12.5 and E13.5 \[[@CR18]\]. While similar regulatory functions for Gli3 have been identified in other cell types (references in \[[@CR18]\]), it remains to be investigated how Gli3 mediates so many distinct effects in the same cell population; and whether these epithelial effects rely on *Gli3* expression prior to mammary induction, on cell-autonomous Gli3 function in the ME, or via tissue-interactions with and *Gli3* expression in the MM (Fig. [1z](#Fig1){ref-type="fig"}).

Mammogenesis Does not Require Gli1 and Gli2, but Only Gli3^R^ {#Sec4}
=============================================================

At E11.5, the somites also express *Gli2*, but not *Gli1* (Fig. [1a, b](#Fig1){ref-type="fig"}) \[[@CR6]\]. Expression of *Gli* genes in the surface ectoderm or mammary tissues is arguable at E12.5, except for notable *Gli3* expression in MR5 (Fig. [1d--k](#Fig1){ref-type="fig"}) as confirmed by RNA-profiling \[[@CR18]\]. By E13.5, *Gli3* and *Gli2* are convincingly expressed in overlap in the ectoderm, mammary epithelium (ME) and mammary mesenchyme (MM) (Fig. [1m,n,p,q](#Fig1){ref-type="fig"}), the latter confirmed for *Gli3* by RNA-profiling \[[@CR18]\] and immunohistochemistry \[[@CR6]\]. Thus, the initial growth defects of *Gli3*^*Xt-J/Xt-J*^ MR2 and MR4 at E11.5 could subsequently be compounded by the lack of *Gli3* in any of the tissue compartments.

Although *Gli2* and *Gli3* overlap in expression, homozygous *Gli2*-null mutants have no mammary induction defect \[[@CR6], [@CR28]\]. Neither have *Gli1-*null, *Gli2*^*lkni/+*^ or *Gli2*^*lkn/lkni*^ mutants which express Gli1^A^ from the endogenous *Gli2* promoter \[[@CR6]\]. However, removing one *Gli3* allele in *Gli2*^*lkni/lkni*^ embryos abolishes induction of MR3 and MR5 as in *Gli3*^*Xt-J/Xt-J*^ embryos. Moreover, *Gli1* is misexpressed in the MM of MR2 in E13.5 *Gli3*^*Xt-J/Xt-J*^ embryos (Fig. [1t](#Fig1){ref-type="fig"}). The high *Gli1* expression in MR1 and MR4 at E13.5 (Fig. [1r, v](#Fig1){ref-type="fig"}) may also reflect misexpression in the MM, similar to such misexpression reported at E14.5 \[[@CR6]\]. Together, these data indicate that Gli3 acts as Gli3^R^ during MR formation \[[@CR6]\] (Fig. [1y, z](#Fig1){ref-type="fig"}), and is the only Gli family member with functional relevance for embryonic mammary development, by repressing *Gli1* transcription, and antagonizing Gli2^A^ function \[[@CR6]\]. Moreover, these data indicate that canonical Hh signaling needs to be in an off-state to allow mammogenesis \[[@CR6]\], at least at the positions of MR3 and MR5.

Mammogenesis Requires Absence of Hh Signaling, Likely to Prevent Acquisition of a Hair Follicle Fate {#Sec5}
====================================================================================================

The above-described repressor function of Gli3 and absence of *Shh*, *Ihh, Gli1* and *Ptc1* expression in the surface ectoderm or dermal mesenchyme at the time of ML and MR induction \[[@CR6]\] (our unpublished data and Fig. [1a](#Fig1){ref-type="fig"}), explain why *Shh*^*−/−*^ and *Ihh*^*−/−*^ mutant mice have no mammary induction defect \[[@CR2], [@CR3]\]. All together, these data indicate Hh signaling is not required for induction of any of the five MRs. While normally, *Shh, Ihh* and *Ptc1* are expressed in the ME from E12.5 onward and in postnatal stages \[[@CR3]\], the normal outgrowth of transplanted E12.5 *Shh*^*−/−*^ and *Ihh*^*−/−*^ ME in cleared wild-type mammary fat pads or under the kidney capsule, indicates that epithelial Hh signaling or mesenchymal Shh is not either required during later embryonic and postnatal stages \[[@CR2]\].

Interestingly, activating components of the Hh signaling cascade become expressed in the surface ectoderm and ME only *after* the formation of MR, but *prior to* hair follicle formation \[[@CR3]\]. Moreover, *Shh* is required for hair follicle development \[[@CR2], [@CR3]\]. We therefore propose that the off-state of Hh signaling is a discriminatory factor for the choice of a skin appendage between mammary and either hair or non-mammary fate, and that therefore MRs must develop prior to hair follicle formation, i.e. prior to activation of Hh signaling in the trunk ectoderm \[[@CR29], [@CR30]\]. Such a decisive role for Hh signaling appendage fate requires further investigation, but seems to be confirmed by the glandular appearance of hair follicles when Hh signaling in the skin is ablated in *K14Cre;Smo*^*fl/fl*^ embryos \[[@CR31]\].

Conclusion and Perspectives {#Sec6}
===========================

Gli3 function is critical for embryonic development of MR2-5; in particular Gli^R^-mediated repression of canonical Hh signaling is critical for induction of MR3 and MR5. Its variable requirement for the five MRs in mouse gives perhaps some insight in mechanisms underlying the variation in number of mammary glands among mammalian species. For example, MR3 requires somitic Gli3 as the earliest known effector in a cascade involving FGF10/FGFR2b and subsequent Wnt signaling (Fig. [1y](#Fig1){ref-type="fig"}), but other tissue-interactions and perhaps molecular mechanisms act downstream of Gli3 in early development of other MRs, and remain to be elucidated. Examples of additional interesting avenues for investigation pertain to possible interactions with other important mesenchymal factors in MR3 formation (e.g. Nrg3, Tbx3, or Raldh2 that mediates retinoic acid signaling) \[[@CR32]--[@CR34]\] (Fig. [1y](#Fig1){ref-type="fig"}); whether the sustained protrusion of MR2 in *Gli3*^*Xt-J/Xt-J*^ embryos bears any mechanistic similarity to the protrusion of MRs in wild-type males; and whether Gli3 is involved in non-canonical Hh signaling in mammogenesis.

Given the many molecular similarities between embryonic mammary development and mammary/breast tumors \[[@CR35], [@CR36]\], it is of interest whether GLI3 plays a role in breast cancer. It is noteworthy that GLI(1) was discovered as an oncogene, and like GLI2 and SHH, is upregulated in various cancers \[[@CR13]\]. HH signaling is considered a therapeutic target for breast cancer, as GLI(1) upregulation predicts a poor prognosis for estrogen receptor negative or triple negative breast cancers \[[@CR37]--[@CR39]\]. Yet, GLI3 is seldom reported in association with cancer \[[@CR13]\]. In absolute number and relative *Gli1*, only few somatic mutations in *Gli3* have been found in breast cancer samples \[COSMIC database, Sanger institute\]. It would be of interest to determine whether these *Gli3* mutations relate to *Gli1* upregulation, and whether they have any diagnostic or prognostic value.
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